GIOTRIF rPMS in Korean Patients With NSCLC

Boehringer Ingelheim1,272 enrolled

Overview

To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Study Type

OBSERVATIONAL

Enrollment

1,272

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

GIOTRIF 20mgDRUG

NSCLC with GIOTRIF 20mg

GIOTRIF 40mgDRUG

NSCLC with GIOTRIF 40mg

GIOTRIF 30mgDRUG

NSCLC with GIOTRIF 30mg

Eligibility

Sex: ALLMin age: 19 YearsMax age: 110 Years

Medical Language ↔ Plain English

Inclusion criteria: 1. Patients who have been started on GIOTRIF® in accordance with the approved label in Korea 2. Age = 19 years at enrolment 3. Patients who have signed on the data release consent form Exclusion criteria: 1. Known hypersensitivity to afatinib or any of its excipients 2. Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption 3. Patients for whom GIOTRIF® is contraindicated according to the local label

Locations (1)

Unnamed facility

Multiple Locations, South Korea

Outcomes

Primary Outcomes

Percentage of Participants With Adverse Drug Reactions (ADRs)

Percentage of participants with Adverse Drug Reactions (ADRs).

Time frame: From baseline (Visit 1) until last visit (the last follow-up visit a patient actually attended during the study), up to 1051 days.

Secondary Outcomes

Progression-Free Survival (PFS) Rate at 48 Weeks

Progression-Free Survival (PFS) rate, defined as the percentage of patients who were alive and without disease progression at the 48-week tumour assessment. Progression was assessed by the investigator according to local standard pattern of care for non-small cell lung cancer (NSCLC). If a patient is known to have progressed, but the date of progression is not attainable, the last date when the patient was assessed will be used as date of progression. PFS rate at 48 weeks was estimated using Kaplan-Meier estimates on the PFS curve.

Time frame: From week 0 until week 48. Up to 48 weeks.

Percentage of Participants With Best Response

Best response is defined as the best response observed in individual subject from the date of the first administration of the study medication until the earliest recording of Progressive disease (PD), death, or end of treatment (as long as no additional anti-cancer therapy was implemented). Disease Assessment will be based on the assessment of cancer related symptoms and, if available, radiologic assessments as per standard of care at the site. Tumour response according to investigator's assessment Each patient will be assigned to one of the following categories: 1. Complete response (CR) 2. Partial response (PR) 3. Stable disease (SD) 4. Progressive disease (PD) 5. Not evaluable for response, reasons to be specified (e.g. early death, tumour assessments incomplete, etc.)

Time frame: Tumour assessments performed at week 0, 8±2, 24±2 and 48±2. Up to 50 weeks.

Overall Survival (OS)

Overall Survival (OS), defined as time from the date of the first administration of afatinib to the date of death. Kaplan-Meier estimates and 95% confidence intervals for the 25th, median, and 75th percentiles of the survival distribution will be calculated for OS. For patients with known date of death: OS \[days\] = date of death - (date of start of treatment) + 1 For patients known not death case: OS (censored) \[days\] = date of last contact showing no death - (date of start of treatment) + 1.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.